Cargando…

Integrins as attractive targets for cancer therapeutics

Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor me...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meng, Wang, Ying, Li, Mengwei, Wu, Xuezhen, Setrerrahmane, Sarra, Xu, Hanmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463276/
https://www.ncbi.nlm.nih.gov/pubmed/34589393
http://dx.doi.org/10.1016/j.apsb.2021.01.004
_version_ 1784572367538749440
author Li, Meng
Wang, Ying
Li, Mengwei
Wu, Xuezhen
Setrerrahmane, Sarra
Xu, Hanmei
author_facet Li, Meng
Wang, Ying
Li, Mengwei
Wu, Xuezhen
Setrerrahmane, Sarra
Xu, Hanmei
author_sort Li, Meng
collection PubMed
description Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor metastasis. The role of integrins in tumor progression makes them promising targets for cancer treatment, and certain integrin antagonists, such as antibodies and synthetic peptides, have been effectively utilized in the clinic for cancer therapy. Here, we discuss the evidence and knowledge on the contribution of integrins to cancer biology. Furthermore, we summarize the clinical attempts targeting this family in anti-cancer therapy development.
format Online
Article
Text
id pubmed-8463276
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84632762021-09-28 Integrins as attractive targets for cancer therapeutics Li, Meng Wang, Ying Li, Mengwei Wu, Xuezhen Setrerrahmane, Sarra Xu, Hanmei Acta Pharm Sin B Review Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor metastasis. The role of integrins in tumor progression makes them promising targets for cancer treatment, and certain integrin antagonists, such as antibodies and synthetic peptides, have been effectively utilized in the clinic for cancer therapy. Here, we discuss the evidence and knowledge on the contribution of integrins to cancer biology. Furthermore, we summarize the clinical attempts targeting this family in anti-cancer therapy development. Elsevier 2021-09 2021-04-10 /pmc/articles/PMC8463276/ /pubmed/34589393 http://dx.doi.org/10.1016/j.apsb.2021.01.004 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Li, Meng
Wang, Ying
Li, Mengwei
Wu, Xuezhen
Setrerrahmane, Sarra
Xu, Hanmei
Integrins as attractive targets for cancer therapeutics
title Integrins as attractive targets for cancer therapeutics
title_full Integrins as attractive targets for cancer therapeutics
title_fullStr Integrins as attractive targets for cancer therapeutics
title_full_unstemmed Integrins as attractive targets for cancer therapeutics
title_short Integrins as attractive targets for cancer therapeutics
title_sort integrins as attractive targets for cancer therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463276/
https://www.ncbi.nlm.nih.gov/pubmed/34589393
http://dx.doi.org/10.1016/j.apsb.2021.01.004
work_keys_str_mv AT limeng integrinsasattractivetargetsforcancertherapeutics
AT wangying integrinsasattractivetargetsforcancertherapeutics
AT limengwei integrinsasattractivetargetsforcancertherapeutics
AT wuxuezhen integrinsasattractivetargetsforcancertherapeutics
AT setrerrahmanesarra integrinsasattractivetargetsforcancertherapeutics
AT xuhanmei integrinsasattractivetargetsforcancertherapeutics